NCT01139970 - Veliparib and Temozolomide in Treating Patients With Acute Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2010

Primary Completion Date

March 21, 2014

Study Completion Date

February 22, 2026

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2AAdult Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARAAdult B Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Adult T Acute Lymphoblastic LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Temozolomide

Given PO

DRUG

Veliparib

Given PO

Trial Locations (3)

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

60637

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH